BiotechTube

Comparator: sitagliptin phosphate + Comparator: pioglitazone + Comparator: placebo to pioglitazone + Comparator: placebo to sitagliptin

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes Mellitus (T2DM)

Conditions

Type 2 Diabetes Mellitus (T2DM)

Trial Timeline

Jul 11, 2007 → Feb 24, 2009

NCT ID
NCT00511108

About Comparator: sitagliptin phosphate + Comparator: pioglitazone + Comparator: placebo to pioglitazone + Comparator: placebo to sitagliptin

Comparator: sitagliptin phosphate + Comparator: pioglitazone + Comparator: placebo to pioglitazone + Comparator: placebo to sitagliptin is a phase 1 stage product being developed by Merck for Type 2 Diabetes Mellitus (T2DM). The current trial status is completed. This product is registered under clinical trial identifier NCT00511108. Target conditions include Type 2 Diabetes Mellitus (T2DM).

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00511108Phase 1Completed

Competing Products

20 competing products in Type 2 Diabetes Mellitus (T2DM)

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85